Background: In previous studies, significantly elevated levels of vascular endothelial growth factor (VEGF) have been reported in patients with severe obstructive sleep apnea-hypopnea syndrome (OSAHS). On the other hand, plasma tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) have been significantly higher in mild sleep apneics than in normal controls. However, this study included a small number of patients and milder cases of OSAHS. Objectives and Methods: To assess the involvement of IL-6 and TNF-α in VEGF increases in patients with severe OSAHS, serum levels of IL-6 and TNF-α were determined in patients with severe OSAHS (n = 110) and compared to those of controls (n = 45) using an enzyme-linked immunosorbent assay. Results: No significant increase in IL-6 or TNF-α was detected in the present study cohort. However, the body mass index was significantly correlated with the severity of the apnea-hypopnea index. Conclusions: These data suggest that the elevation in VEGF is not directly related to IL-6 or TNF-α levels. However, the question of whether VEGF is the cause or the result of OSAHS remains to be determined. Further studies are needed to clarify the role of IL-6 and TNF-α in the pathogenesis of OSAHS, in which obesity should be entered as an independent factor.

Keywords:
Body mass index, Interleukin-6, Sleep apnea, Tumor necrosis factor-α, Vascular endothelial growth factor
1.
Imagawa S, Yamaguchi Y, Higuchi M, Neichi T, Hasegawa Y, Mukai HY, Suzuki N, Yamamoto M, Nagasawa T: Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea-hypopnea syndrome. Blood 2001;98:1255–1257.
2.
Gozal D, Lipton AJ, Jones KL: Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea. Sleep 2002;25:59–65.
3.
Pazlicek V, Marti HH, Grad S, Gibbs JS, Kol C, Wenger RH, Gassman M, Kohl J, Maly FE, Oelz O, Koller EA, Schirlo C: Effects of hypobaric hypoxia on vascular endothelial growth factor and the acute phase response in subjects who are susceptible to high-altitude pulmonary oedema. Eur J Appl Physiol 2000;81:497–503.
4.
Christou H, Yoshida A, Arthur V, Morita T, Kourenbanas S: Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 1993;18:768–776.
5.
Bondestam J, Salven P, Jaankela-Saari H, Ikonen T, Lepantalo M, Mattila S, Joensuu H: Major surgery increases serum levels of vascular endothelial growth factor only temporarily. Am J Surg 2000;179:57–59.
6.
Richard DE, Berra E, Ponyssegur J: Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J Biol Chem 2000;275:26765–26771.
7.
Vgontzas AN, Papanicolaou DA, Bixlen EO, Kales A, Tyson K, Chrousos GP: Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313–1316.
8.
Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, Kales A, Chrousos GP: Sleep apnea and daytime sleepiness and fatigue: Relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151–1158.
9.
Bifel WL, Moore EE, Moore FA, Peteson VM: Interleukin-6 in the injured patient. Ann Surg 1996;224:647–664.
10.
Fox GL, Whalley DG, Began OR: Anesthesia for the morbidly obese: Experience with 110 patients. Br J Anaesth 1981;83:811–816.
11.
Kaspäs L, Hong L, Cady AB, Opp MR, Postlethwaite AE, Seyer JM, Krueger JM: Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor-alpha and TNF-alpha fragments. Am J Physiol 1992;263:R708–R715.
12.
Opp MR, Kaspas L, Toth LA: Cytokine involvement in regulation of sleep. Proc Soc Exp Biol Med 1992;201:16–27.
13.
Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A, Gelman S: Raised interleukin-6 levels in obese patients. Obes Res 2000;8:673–675.
14.
Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993;259:87–91.
15.
Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP: The differential effect of food intake and β-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 1999;84:2126–2133.
16.
Beisel WR: Herman Award Lecture: Infection-induced malnutrition – From cholera to cytokines. Am J Clin Nutr 1995;62:813–819.
17.
Sarraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivet DJ III, Flier JS, Lowell BB, Fraker DL, Alexander HR: Multiple cytokines and acute inflammation raise mouse leptin levels: Potential role in inflammatory anorexia. J Exp Med 1997;185:171–175.
18.
Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE, Griveas I, Katsilambros N, Flier JS: Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans. J Clin Endocrinol Metab 1997;82:3408–3413.
19.
Zumbach MS, Wolfgang M, Boehme J, Wahl P, Stremmel W, Ziegler R, Nawroth PP: Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab 1997;82:4080–4082.
20.
de Courten M, Zimmet P, Hodge A, Collins V, Nicolson M, Staten M, Dowse G, Alberti KG: Hyperleptinaemia: The missing link in the metabolic syndrome? Diabet Med 1997;14:200–208.
21.
Shek EW, Brands MW, Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 1998;31:409–414.
22.
Gunga HC, Kirsch K, Rocker L, Behn C, Koralewski E, Davila EH, Estrade MI, Johannes B, Wittels P, Jelkmann W: Vascular endothelial growth factor in exercising humans under different environmental conditions. Eur J Appl Physiol 1999;79:484–490.
23.
Marti HH, Risau W: Systemic hypoxia changes the organ specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 1998;95:15809–15814.
24.
McColley SA, Stellmach V, Boas SR, Jain M, Grawford SE: Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 2000;161:1877–1880.
25.
Los M, Aarsman CJ, Terpstra L, Wittebol-Post D, Lips CJ, Blijham GH, Voest EE: Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Ann Oncol 1997;10:1015–1022.
26.
Takano S, Yochii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tissue patients. Cancer Res 1996;56:2185–2190.
27.
Speirs V, Atkin ST: Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumors. Br J Cancer 1999;80:898–903.
28.
Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K: Circulating vascular endothelial growth factors in patients with colorectal cancer. Am J Gastroenterol 1998;93:269–252.
29.
Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y: Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998;34:2041–2045.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.